Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Squamous Cell Carcinoma (Skin)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT04510129
What this trial is testing

Cancer Biospecimen Collection Study

Who this might be right for
Cancer of Head and NeckLung Cancer, Nonsmall CellSmall-cell Lung Cancer+8 more
Cofactor Genomics, Inc. 1,650
Very early researchStudy completedNCT02646319
What this trial is testing

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Who this might be right for
Advanced Malignant NeoplasmCervical Squamous Cell CarcinomaEndometrial Carcinoma+29 more
Mayo Clinic 2
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Early research (Phase 1)Study completedNCT01391143
What this trial is testing

Safety Study of MGA271 in Refractory Cancer

Who this might be right for
Prostate CancerMelanomaRenal Cell Carcinoma+4 more
MacroGenics 179
Early research (Phase 1)Ended earlyNCT02952989
What this trial is testing

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellBreast Neoplasms+5 more
Seagen Inc. 47
Testing effectiveness (Phase 2)Study completedNCT03989115
What this trial is testing

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Who this might be right for
Solid Tumor
Revolution Medicines, Inc. 113
Early research (Phase 1)Active Not RecruitingNCT06238479
What this trial is testing

LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more
Eli Lilly and Company 490
Early research (Phase 1)Active Not RecruitingNCT05277051
What this trial is testing

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 152
Post-approval studies (Phase 4)Looking for participantsNCT07405086
What this trial is testing

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Who this might be right for
Advanced Biliary Tract CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Hepatocellular Carcinoma+18 more
OHSU Knight Cancer Institute 160
Not applicableLooking for participantsNCT07682831
What this trial is testing

Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies

Who this might be right for
Basal Cell Carcinoma of SkinSquamous Cell Carcinoma (Skin)
University of Rochester 92
Not applicableStudy completedNCT01614002
What this trial is testing

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Who this might be right for
Carcinoma
Onkovis GmbH 371
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Not applicableStudy completedNCT02131805
What this trial is testing

Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

Who this might be right for
Cutaneous Basal CellSquamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center 36
Not applicableLooking for participantsNCT04068155
What this trial is testing

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

Who this might be right for
Skin CancerCutaneous TumorCutaneous Metastasis
Alpha Tau Medical LTD. 80
Not applicableActive Not RecruitingNCT05724875
What this trial is testing

FLASH Radiotherapy for Skin Cancer

Who this might be right for
Basal Cell CarcinomaCutaneous Squamous Cell Carcinoma
Centre Hospitalier Universitaire Vaudois 60
Not applicableUnknownNCT01980264
What this trial is testing

Harmonics-based in Vivo Optical Virtual Biopsy

Who this might be right for
Healthy Participants With Different Skin Types and Different AgesDiseased Participants With Different Skin Types and Different AgesParticipants Suffered From Diabetes With Different Skin Types and Different Ages
National Taiwan University Hospital 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT04180371
What this trial is testing

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Who this might be right for
Advanced Solid Tumor Historically Known for High EphA2 ExpressionUrothelial CancerOvarian Cancer+4 more
BicycleTx Limited 288
Early research (Phase 1)Ended earlyNCT05432193
What this trial is testing

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerEsophageal Cancer+4 more
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 20
Next Page